COVID-19：熊本大学成功制造电晕抗体：对突变株有效
2021/07/14
熊本大学：
该研究小组已成功制造出针对新冠的抗体。
“对突变株有效的治疗药物”很可能从熊本诞生。
熊本大学
松下修造特聘教授
对于那些感染了突变株的人，可以预期“预防恶化和预防感染的效果与疫苗相同”。
熊本大学松下教授研制的中和抗体。
新冠抗体的产生：
新冠抗体与新冠病毒表面的突起物结合，阻止病毒侵入细胞。
它从病情严重并随后迅速康复的患者的细胞中复制。
对英国型和印度型等两种突变株均证实了该效果。
特聘松下教授：
“它的效果非常好，数量巨大。效果惊人。”
1/100 剂量：
它是美国紧急批准并用于治疗的中和抗体剂量的百分之一。
意味着可以预期有防止阳性患者病情加重的效果。
KAB熊本朝日广播»新闻
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19:
Highlights
• Neutralizing mAbs against SARS-CoV-2 are isolated from two convalescent patients
• Efficacy of antibodies is maintained against B.1.1.7 and mink cluster 5 variants
• B.1.351 from South Africa and P.1 from Brazil are resistant to mAbs and plasmas
• mAbs with high affinity for the RBD efficiently cross-neutralize B.1.351 and P.1
Summary
Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs)
is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants,
we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG+) memory B cells.
Cell Reports